Tag Archives: EGFRm NSCLC

Final FLAURA2 Results Confirm Survival Advantage of Tagrisso Plus Chemotherapy in Advanced EGFRm Lung Cancer

(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves survival for patients with first-line advanced EGFR-mutated NSCLC. The data reinforce Tagrisso as the foundational therapy in this setting, building … Read the full press release